SAN DIEGO, July 27 /PRNewswire/ — Millennium Laboratories,
Inc., a national, research-based medication monitoring company
specifically focused on clinicians who treat chronic pain, strongly
advocated for an increase in physician reimbursement for
point-of-care urine drug screening at the Annual Clinical
Laboratory Public Meeting of the
Centers for Medicare and Medicaid Services (CMS) on July 22, 2010. As the only therapeutic drug
monitoring company presenting, Millennium was continuing its
advocacy campaign, launched in June of 2009, supporting fair
reimbursement for point-of-care (POC) urine drug screen
devices.
James
Slattery, Millennium Laboratories founder and CEO, explained
the company’s presence at the meeting. “We are advocating for a
higher, though moderate, reimbursement level to physicians for
performing drug screening tests. Millennium as a corporation has no
financial stake in this argument. It is simply the right thing to
do for all parties involved.”
In 2009 CMS drastically cut reimbursement for point-of-care test
(POCT) devices used in urine drug screening. Millenni
‘/>”/>
SOURCE